![]() ![]() The clinical convenience of A1c testing has the potential to facilitate screening those at risk and provide the opportunity for early diagnosis and intervention.īecause of A1c’s integral role in diagnosis and treatment, it is important to recognize clinical scenarios and interfering factors that yield false results. 4 In addition, because there is no need for fasting or timed samples, the A1c test is more clinically convenient. Recommending A1c as a diagnostic test was partly based on its advantages over timed glucose tests, including serving as a better index of overall glycemic exposure and risk for long-term complications, offering less biologic variability and preanalytic instability, and being unaffected by acute perturbations in glucose levels due to an acute illness or stress-related event. 3 The value of 6.5 % was selected as an optimal cut point for detecting prevalent retinopathy consistent with the definition used for current fasting (≥126 mg/dL) and 2-h (≥200 mg/dL) plasma glucose cut points. The role of the A1c broadened in 2010 when the ADA added A1c ≥6.5 % as a diagnostic criterion for diabetes, allowing the test to be used for both management and diagnosis. 2 Other key studies, such as the United Kingdom Prospective Diabetes Study (UKPDS), have consistently demonstrated the correlation between A1c and diabetes complications and have reinforced currently recommended target values. 1 In 1993, the landmark Diabetes Control and Complications Trial (DCCT) demonstrated its importance as a predictor of diabetes-related outcomes, and the ADA started recommending specific A1c targets in 1994. ![]() A1c assays became commercially available in 1978, and the American Diabetes Association (ADA) first recommended using A1c in 1988. For decades, hemoglobin A1c (A1c) has remained the standard biomarker for glycemic control. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |